Renaissance Capital logo

Orchestra BioMed (Health Sciences Acquisitions 2)

Priced, Nasdaq: OBIO

Second blank check company formed by RTW Investments to acquire a biopharma or medtech business (completed 1/27/2023).

Industry: SPAC

First Day Return: +14.0%

Health Sciences Acquisitions Corporation 2 is a newly incorporated blank check company. Although there is no restriction or limitation on what industry our target operates in, it is our intention to pursue prospective targets that are focused on healthcare innovation. We anticipate targeting companies domiciled in North America or Europe that are developing assets in the biopharma and medical technology sectors, which aligns with our management team’s experience in healthcare investing and drug development. Our sponsor is an affiliate of RTW Investments, a New York based financial firm managing more than $4.4 billion of regulatory assets under management, as of May 31, 2020. RTW was formed in 2009 by Roderick Wong, MD, and has garnered a reputation as a leading capital provider to healthcare industry entrepreneurs and academic investigators due to its investment expertise, deep industry relationships, benevolent activism, and long-standing track record. Our management team will be led by Dr. Roderick Wong and Dr. Naveen Yalamanchi, Chief Investment Officer and Portfolio Manager of RTW, respectively.
IPO Data
IPO Date 08/03/2020
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $139
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters New York, NY, United States
Founded 2020
Employees at IPO 4
Website www.rtwfunds.com

Orchestra BioMed (Health Sciences Acquisitions 2) (OBIO) Performance